Intra-Cellular Therapies, Inc.
ITCI
Hisse Senetlerindeki Sıralama
#1693
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Hisse Fiyatı
$131.87
Son senkronizasyon: 2025-04-02
Piyasa Değeri
$12.68B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Intra-Cellular Therapies, Inc. (ITCI) için EPS
December 2024 itibariyle EPS TTM: $-0.01
Intra-Cellular Therapies, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) $-0.01'dir. 2023 yılı sonunda, şirketin EPS'si $-1.46 idi; bu, 2022 yılındaki EPS olan $-2.72 ile önceki yıla göre azalma.
Intra-Cellular Therapies, Inc. için 2013 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
| Yıl | EPS | Değiştir |
|---|---|---|
| 2026 (TTM) | $-0.01 | -98.61% |
| 2024 | $-0.72 | -50.68% |
| 2023 | $-1.46 | -46.32% |
| 2022 | $-2.72 | -22.29% |
| 2021 | $-3.50 | 8.36% |
| 2020 | $-3.23 | 20.52% |
| 2019 | $-2.68 | -5.63% |
| 2018 | $-2.84 | 33.96% |
| 2017 | $-2.12 | -21.19% |
| 2016 | $-2.69 | -7.56% |
| 2015 | $-2.91 | 171.96% |
| 2014 | $-1.07 | -31.41% |
| 2013 | $-1.56 | 0.00% |
Benzer şirketler veya rakipler için EPS
| Şirket | EPS | EPS Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -5,663.00% |
IN
|
